Contezolid
Phase 3Small molecule
Contezolid is one of 69 small molecule programs targeting Abscess. It is currently in Phase 3.
4
Indications
6
Total Trials
6
Active Trials
68
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
82 competitors in Tuberculosis
#DrugCompanyPhaseTrials
1Rifadin
SanofiPhase 3
Avelox
BayerPhase 3
Zyvox
PfizerPhase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Lamprene
NovartisPhase 3
Sirturo
WWim Janssens
Phase 3
Levaquin
WWim Janssens
Phase 3
TB Alliance
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Deltyba
OtsukaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tuberculosis2 trials
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Active, not recruiting·—·Phase 3·NCT06081361·186 enrolled
Phase II Clinical Study of Contezolid for the Treatment of Bone and Joint Tuberculosis
Enrolling by invitation·—·Phase 1/2·NCT06811012·24 enrolled
Abscess1 trial
Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease
Enrolling by invitation·—·Phase 2·NCT07372781·24 enrolled
Meningitis1 trial
Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis
Enrolling by invitation·—·Phase 1/2·NCT06811025·24 enrolled
Mycobacterium Avium Complex Pulmonary Disease1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Contezolid. EMBL-EBI & Wellcome Sanger Institute.
- [4]